These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27704562)

  • 1. Efavirenz does not meaningfully affect the single dose pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Siringhaus T; Herpok L; Bethel-Brown C; Manthos H; Brejda J; Gartner M
    Biopharm Drug Dispos; 2016 Dec; 37(9):542-549. PubMed ID: 27704562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
    Krishna R; East L; Larson P; Valiathan C; Deschamps K; Luk JA; Bethel-Brown C; Manthos H; Brejda J; Gartner M
    Biopharm Drug Dispos; 2016 Dec; 37(9):533-541. PubMed ID: 27696440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
    J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.
    Yee KL; Sanchez RI; Auger P; Liu R; Fan L; Triantafyllou I; Lai MT; Di Spirito M; Iwamoto M; Khalilieh SG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.
    Joseph D; Rose P; Strelkowa N; Schultz A; Garcia J; Elgadi M; Huang F
    J Clin Pharmacol; 2015 Apr; 55(4):384-91. PubMed ID: 25352040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.
    Krishna R; Rizk ML; Larson P; Schulz V; Kesisoglou F; Pop R
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):196-206. PubMed ID: 28419778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
    Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
    Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects.
    Liu P; Foster G; LaBadie RR; Gutierrez MJ; Sharma A
    J Clin Pharmacol; 2008 Jan; 48(1):73-84. PubMed ID: 18025525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
    de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
    Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug-drug interaction study between raltegravir and citalopram.
    Blonk MI; Langemeijer CC; Colbers AP; Hoogtanders KE; van Schaik RH; Schouwenberg BJ; Burger DM
    Antivir Ther; 2016; 21(2):143-52. PubMed ID: 26375942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenz.
    Mogatle S; Skinner M; Mills E; Kanfer I
    S Afr Med J; 2008 Dec; 98(12):945-9. PubMed ID: 19374071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
    Wenning LA; Hanley WD; Brainard DM; Petry AS; Ghosh K; Jin B; Mangin E; Marbury TC; Berg JK; Chodakewitz JA; Stone JA; Gottesdiener KM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2852-6. PubMed ID: 19433563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
    Wenning LA; Petry AS; Kost JT; Jin B; Breidinger SA; DeLepeleire I; Carlini EJ; Young S; Rushmore T; Wagner F; Lunde NM; Bieberdorf F; Greenberg H; Stone JA; Wagner JA; Iwamoto M
    Clin Pharmacol Ther; 2009 Jun; 85(6):623-7. PubMed ID: 19279563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
    Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
    Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
    Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
    Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
    Iwamoto M; Hanley WD; Petry AS; Friedman EJ; Kost JT; Breidinger SA; Lasseter KC; Robson R; Lunde NM; Wenning LA; Stone JA; Wagner JA
    Antimicrob Agents Chemother; 2009 May; 53(5):1747-52. PubMed ID: 19223645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.